Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1737)	1/31/2007 3:57:54 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

CYTR made a 3Yrs. H, the stock has doubled since Nov. bigcharts.marketwatch.com It is CEO,Tod Woolf,Ph.D. will present tomorrow at the MHT 5th annual BioForum on a panel titled, "RNAi: Talking Outloud About Gene Silencing." CYTR next resistance is now its May 2003 H at 3.74 bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (1737)	10/8/2007 2:27:25 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

NTII Is up 20% & trading above the $4 level. finance.yahoo.com Apparently it has a chance to keep its listing on the Naz In spite of last week's warning.<g> Nasdaq warns Neurobiological Technologies bizjournals.com Monday October 1, 11:06 am ET The Nasdaq Stock Market warned Neurobiological Technologies Inc. that its stock could be delisted because it doesn't meet the exchange's minimum market value for listed securities. Emeryville-based Neurobiological Technologies (NASDAQ: NTII - News) is developing the drug viprinex, made from Malayan pit viper venom, to treat ischemic stroke. The company, led by CEO Paul Freiman, said it will appeal the decision and should be able to meet the Nasdaq requirement after completing a public offering of up to $65 million of its stock. The company registered with regulators for the offering on Aug. 13, and hopes to close the sale this month. Bernard